Evidence map›Paper›PMID 39297075›Full record

ArticleGynecologic oncology reports2024

Germline genetic testing reveals pathogenic variants in uterine serous carcinoma patients.

Katelyn Tondo-Steele, Kara J Milliron, Jean H Siedel, Shitanshu Uppal, Sofia D Merajver, Karen McLean

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katelyn Tondo-SteeleDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
Kara J MillironBreast and Ovarian Cancer Risk Evaluation Program, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
Jean H SiedelDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
Shitanshu UppalDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
Sofia D MerajverBreast and Ovarian Cancer Risk Evaluation Program, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
Karen McLeanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.

Funding

Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA DamageR01CA251198 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCLEAN, KAREN · 2020 to 2024
$1.9M
NCI NIH HHS R01 CA251198
6 · The paper itself

Abstract

An increase in the risk of developing uterine serous carcinoma (USC) has been observed among

Indexed as

BRCAGenetic counselingGenetic testingPathogenic variantUterine serous carcinoma

Identifiers

PMID39297075
PMCPMC11408757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.